Pharmaceutical Research & Drug Development – Page 15

Prototype not scalable during scale-up preparation – CMC risk assessment and mitigation

Understanding the signs of potential failure during the scale-up process is critical for timely intervention. Symptoms may manifest in various forms across the operations floor or laboratory settings:Click to read…

Dissolution variability unexplained during tech transfer – how to redesign formulation strategy

Dissolution variability often surfaces as unexpected results during routine testing or product evaluations. Key symptoms and signals include:Click to read the full article.

QbD elements missing during regulatory review – regulatory expectations for formulation data

Identifying signals of potential issues at the formulation development stage is essential for mitigating risks associated with QbD elements missing during regulatory reviews. Key symptoms may include:Click to read the…

Excipient incompatibility identified late during regulatory review – CMC risk assessment and mitigation

Recognizing symptoms of excipient incompatibility early can save time and resources. The following signals can indicate a potential incompatibility:Click to read the full article.

Bioavailability risk flagged during early development – data package strengthening approach

Recognizing early indicators of bioavailability risk is critical for timely intervention. Here are common symptoms to look for in manufacturing or laboratory settings:Click to read the full article.

Dissolution variability unexplained during early development – data package strengthening approach

Identifying dissolution variability begins with observing key symptoms or signals either on the production floor or within laboratory settings. The following are primary indicators that suggest potential issues with dissolution…

Bioavailability risk flagged during IND/NDA filing – regulatory expectations for formulation data

Identifying symptoms of bioavailability risks early can prevent larger problems during development and regulatory reviews. Signs may include:Click to read the full article.

Excipient incompatibility identified late during early development – how to redesign formulation strategy

Identifying the symptoms of excipient incompatibility early can significantly alter the course of development. Common signals may manifest as:Click to read the full article.

QbD elements missing during tech transfer – preventing late-stage reformulation

Deficiencies in the tech transfer process often manifest through various indicators on the production floor and in laboratory analysis. Recognizing these symptoms early is crucial for effective response. Common signals…

Process variability exceeds limits during validation planning – preventing downstream validation failure

Symptoms of process variability can manifest across various operational areas—from production lines to laboratory analyses. It is crucial to recognize these early signals to implement prompt containment measures. Common symptoms…

Control strategy inadequate during validation planning – regulatory scrutiny risk

Identifying early warning signals can be critical in avoiding extended downtimes or regulatory repercussions. Symptoms of an inadequate control strategy may include:Click to read the full article.

Design space poorly justified during development studies – process robustness improvement framework

Effective Framework for Addressing Poorly Justified Design Space in Development Studies In the pharmaceutical industry, poorly justified design spaces during development studies can pose significant risks to process robustness, regulatory…